Agios Pharma (AGIO) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Agios Pharma (AGIO) PT Raised to $80 at Credit Suisse; 'Platform opportunities beyond IDH'
February 15, 2018 8:59 AM ESTCredit Suisse raised its price target on Agios Pharma (NASDAQ: AGIO) to $80.00 (from $66.00) while maintaining a Outperform rating.
... MoreAgios Pharma (AGIO) PT Raised to $90 at Leerink Partners
February 15, 2018 7:33 AM ESTLeerink Partners raised its price target on Agios Pharma (NASDAQ: AGIO) to $90.00 (from $85.00) while maintaining a Outperform rating.
... MoreAgios Pharma (AGIO) PT Raised to $86 at Needham & Company; 'Continued Execution'
February 14, 2018 12:48 PM ESTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $86.00 (from $72.00) while maintaining a Buy rating.
Analyst Chad Messer commented, " Agios made broad progress across its growing pipeline in 2017 and we expect another busy year with their 2nd drug launch and... More
